[HTML][HTML] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - Elsevier
PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of
the present study was to compare their efficacies in this population. PATIENTS AND
METHODS: The Taiwan Cancer Registry and the National Health Insurance claim
databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who
received gefitinib or erlotinib as third-line therapy. Overall survival (OS) and time to treatment …
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of
the present study was to compare their efficacies in this population. PATIENTS AND
METHODS: The Taiwan Cancer Registry and the National Health Insurance claim
databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who
received gefitinib or erlotinib as third-line therapy. Overall survival (OS) and time to treatment …
以上显示的是最相近的搜索结果。 查看全部搜索结果